RNAZ
$9.68
TransCode Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs and diagnostics for treating and identifying cancer.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
TransCode Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs and diagnostics for treating and identifying cancer. The company's lead therapeutic candidate comprises TTX-MC138 that targets microRNA-10b, a ...
Recent News
Sector Update: Health Care Stocks Advance Late Afternoon
Health care stocks rose late Wednesday afternoon, with the NYSE Health Care Index and the Health Car
Sector Update: Health Care Stocks Advance Wednesday Afternoon
Health care stocks rose Wednesday afternoon, with the NYSE Health Care Index adding 0.3% and the Hea
TransCode Therapeutics to Acquire Polynoma, Receive Investment from CK Life Sciences
TransCode Therapeutics (RNAZ) said Wednesday it has agreed to buy biotechnology immuno-oncology comp
Wall Street Set to Open Higher Wednesday; Dow Rises on Japan Trade Deal
US stocks look set to open higher in Wednesday's trading session after the US announced a trade deal
EXCLUSIVE: TransCode Therapeutics Reports Progress In Early-Stage Study For Lead Cancer Drug
TransCode Therapeutics, Inc. (NASDAQ:RNAZ) announced further progress on Thursday in its Phase 1a clinical trial of TTX-MC138 in patients with metastatic cancer. To date, 13 patients have received at least one dose of TTX-MC138 at four separate dose levels ranging from 0.8 mg/kg to 4.8 mg/kg. Two patients have been treated in the expanded enrollment. Eight patients remain on the study for continued treatment, receiving an additional dose of TTX-MC138 during each 28-day treatment cycle, and may r